Showing results (2151-2160 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|June 22, 2012
Anandamide dysfunction in prodromal and established psychosisF Markus LewekeCurrent Pharmaceutical Design|June 22, 2012
The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factorsNicholas Myles, Hannah Newall, Olav Nielssen, et al.Current Pharmaceutical Design|June 22, 2012
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studiesCharlotte Rapp, Hilal Bugra, Anita Riecher-Rössler, et al.Current Pharmaceutical Design|June 22, 2012
Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis researchKerri A Schoedel, Sarah Jane HarrisonCurrent Pharmaceutical Design|June 22, 2012
Neurocognitive functioning and cannabis use in schizophreniaAviv Segev, Shaul Lev-RanCurrent Pharmaceutical Design|June 22, 2012
Can cannabis increase the suicide risk in psychosis? A critical reviewGianluca Serafini, Maurizio Pompili, Marco Innamorati, et al.Current Pharmaceutical Design|June 26, 2012
Clinical use of aspirin in ischemic heart disease: past, present and futureRaffaele De Caterina, Giulia RendaCurrent Pharmaceutical Design|June 26, 2012
Development and clinical use of prasugrel and ticagrelorShiraz Ahmad, Robert F StoreyCurrent Pharmaceutical Design|June 26, 2012
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery diseaseJose Luis Ferreiro, Dominick J AngiolilloCurrent Pharmaceutical Design|June 26, 2012
Pharmacogenetics of clopidogrelStephen A O'Connor, Jean-Sebastien Hulot, Johanne Silvain, et al.Pageof 1,008